Neoplasia in immunosuppressed renal transplant patients: a 20-year experience.
This review examines a 20-year experience in renal transplantation at our center to determine the effects of immunosuppression on the subsequent development of malignancies. Twenty patients had 21 malignancies from primary sites other than skin, yielding an incidence of 2.5%. There were 0.65 malignancies for each 100 cumulative patient years of immunosuppression. Suppression of the host immune response is associated with an increased incidence of malignancies.
D000293:Adolescent; D000328:Adult; D000368:Aged; D000961:Antilymphocyte Serum / Q000009:adverse effects; D001379:Azathioprine / Q000009:adverse effects; D002102:Cadaver; D002648:Child; D002675:Child, Preschool; D003520:Cyclophosphamide / Q000009:adverse effects; D004322:Drainage; D005260:Female; D006084:Graft Rejection / Q000187:drug effects / Q000528:radiation effects; D006801:Humans; D007165:Immunosuppression Therapy / Q000009:adverse effects*; D007166:Immunosuppressive Agents / Q000009:adverse effects*; D016030:Kidney Transplantation; D007938:Leukemia / Q000453:epidemiology; D008223:Lymphoma / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology* / Q000401:mortality; D011241:Prednisone / Q000009:adverse effects; D012189:Retrospective Studies; D013156:Splenectomy; D013601:T-Lymphocytes / Q000276:immunology; D013897:Thoracic Duct; D014019:Tissue Donors
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D001379:Azathioprine; D011241:Prednisone